BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34531878)

  • 1. Janus Kinase Inhibitors and Cell Therapy.
    Assal A; Mapara MY
    Front Immunol; 2021; 12():740847. PubMed ID: 34531878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
    Schroeder MA; Choi J; Staser K; DiPersio JF
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1125-1134. PubMed ID: 29289756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.
    Mannina D; Kröger N
    Drugs; 2019 Sep; 79(14):1499-1509. PubMed ID: 31359326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
    De Togni E; Cole O; Abboud R
    Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of JAK inhibitors in hematopoietic cell transplantation.
    Salit RB
    Bone Marrow Transplant; 2022 Jun; 57(6):857-865. PubMed ID: 35388118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
    Knaus HA; Rottner T; Baumann CK; Cserna J; Mitterbauer M; Schulenburg A; Rabitsch W; Wohlfarth P
    Transplant Cell Ther; 2022 May; 28(5):260.e1-260.e9. PubMed ID: 35217212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide.
    Solán L; Landete E; Bailén R; Dorado N; Oarbeascoa G; Anguita J; Díez-Martín JL; Kwon M
    Hematol Oncol; 2020 Oct; 38(4):597-603. PubMed ID: 32592410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.
    Kale SD; Mehrkens BN; Stegman MM; Kastelberg B; Carnes H; McNeill RJ; Rizzo A; Karyala SV; Coutermarsh-Ott S; Fretz JA; Sun Y; Koff JL; Rajagopalan G
    Front Immunol; 2020; 11():1311. PubMed ID: 32676080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease.
    Sun X; He Q; Yang J; Wang A; Zhang F; Qiu H; Zhou K; Wang P; Ding X; Yuan X; Li H; Zhang Y; Song X
    Cell Transplant; 2021; 30():9636897211033778. PubMed ID: 34269100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
    Yao JM; Otoukesh S; Kim H; Yang D; Mokhtari S; Samara Y; Blackmon A; Arslan S; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
    Transplant Cell Ther; 2023 Aug; 29(8):515.e1-515.e7. PubMed ID: 37182736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
    Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW
    Trends Pharmacol Sci; 2020 Aug; 41(8):531-543. PubMed ID: 32580895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
    Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
    Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
    Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
    Front Immunol; 2021; 12():738481. PubMed ID: 34630419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Graft-versus-Host Disease: An Update on New Treatment Options.
    Patel DA; Crain M; Pusic I; Schroeder MA
    Drugs; 2023 Jul; 83(10):893-907. PubMed ID: 37247105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant.
    Davies A; Salisbury J; Mehra V; Papa S; Basu T
    Clin Exp Dermatol; 2022 Nov; 47(11):2059-2064. PubMed ID: 36004622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation.
    Stickel N; Hanke K; Marschner D; Prinz G; Köhler M; Melchinger W; Pfeifer D; Schmitt-Graeff A; Brummer T; Heine A; Brossart P; Wolf D; von Bubnoff N; Finke J; Duyster J; Ferrara J; Salzer U; Zeiser R
    Leukemia; 2017 Dec; 31(12):2732-2741. PubMed ID: 28484267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.